Delivery Order SPE2DB22D1106-SPE2DB24FEYQ3

Award Date 6/25/24
Potential Completion Date 6/26/24
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract has an award value of $1,007.26 and covers the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a specialty pharmaceutical product. The contract has a ceiling value of $1,445.62 and runs through April 1, 2025. It is a firm fixed-price delivery order contract type. The contract is not associated with any set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product, with a ceiling value of $1,358.61. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is March 26, 2025. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a specialty medication. The award, valued at $2,821.89, is a delivery order under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. The IDC covers a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,549.18 firm fixed-price delivery order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a pharmaceutical product. The contract has an ultimate completion date of March 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,298.59 Firm Fixed Price Delivery Order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a prescription medication. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,577.04, is for the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a pharmaceutical product. The contract has an ultimate completion date of April 2, 2025. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,505.64 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a medication. The contract has an ultimate completion date of February 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,186.56 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a specialty medication. The contract has an ultimate completion date of January 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $5,022.03, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a prescription medication. The contract has an ultimate completion date of April 9, 2025 and is a Firm Fixed Price arrangement. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is the...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FEYQ3
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a prescription medication. The contract has a firm fixed price and a ceiling value of $2,944.09, with a completion date of June 26, 2024.

Amerisourcebergen holds a large Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This specific award appears to be a delivery order under that broader IDC. The contract does not have a set-aside designation, indicating it was awarded on a full and open competition basis.

Generated 9/24/24, 9:28 AM